ArticleMolecular neurobiology2026
Diosmetin as an Effective Treatment for Cisplatin-Induced Neuropathic Pain in Mice which does not Cause Hepatic or Renal Biomarker Alterations.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Although cancer incidence is increasing globally, early detection and antineoplastic treatment ensure high patient survival rates. Among the chemotherapeutic agents widely used clinically, cisplatin is associated with the development of painful and non-painful peripheral neuropathy symptoms, compromising patient treatment continuity. Preclinical studies have indicated that the transient receptor potential vanilloid 1 (TRPV1) ion channels play a crucial role in chemotherapy-induced neuropathic pain. Currently, only duloxetine is recommended for treating chemotherapy-induced peripheral neuropathy, highlighting the urgent need for novel therapies. Natural products such as diosmetin have shown promising pharmacological potential. Here, we evaluated the effects of diosmetin in a mouse model of cisplatin-induced neuropathic pain (0.23 mg/kg, intraperitoneal). Nociceptive parameters included mechanical allodynia, affective-motivational behaviour, heat hyperalgesia, and muscle strength loss, along with hepatic [aspartate aminotransferase (AST), alanine aminotransferase (ALT)] and renal (urea and creatinine) biomarkers. Diosmetin (0.015, 0.15, and 1.5 mg/kg) administered orally by gavage (p.o.) resulted in antinociceptive effects, reduced mechanical allodynia, and decreased affective motivational behaviours in mice. Diosmetin (0.15 mg/kg) also reduced cisplatin-induced heat hyperalgesia and muscle strength loss, showing an efficacy comparable to that of duloxetine (30 mg/kg, p.o., positive control) and SB-366791 (1 mg/kg p.o., TRPV1 channel antagonist). Additionally, prior desensitisation of TRPV1-positive fibres with subcutaneous resiniferatoxin (RTX) prevents the development of mechanical allodynia and thermal hyperalgesia. Diosmetin (0.15 mg/kg) did not alter hepatic or renal biomarkers. Diosmetin has therapeutic potential for treating pain in patients with neuropathy, and the TRPV1 channel plays a crucial role in cisplatin-induced peripheral neuropathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.